

New Research Innovations in Liquid Biopsy, Bioinformatics and Liquid Handling Advance Future of Precision Medicine

Broad spectrum of technological advances for cancer research on display at AACR 2017

Dateline:

WASHINGTON, D.C.

Thursday, March 30, 2017 8:00 am EDT

WASHINGTON, D.C.--([BUSINESS WIRE](#))--AACR 2017 – [Thermo Fisher Scientific](#), the world leader in serving science, will highlight its latest innovative solutions for research designed to help customers advance the future of precision medicine. The new products and a wide spectrum of [scientific posters](#) will be featured at the American Association for Cancer Research (AACR) 2017 Annual Meeting (booth #1727) at the Walter E. Washington Convention Center.

“
“Advancements in
precision medicine are driving
the need for innovative
technologies designed to help
our customers better
understand the molecular
makeup of disease so they may
more effectively treat cancer in
the future”
”

“Advancements in precision medicine are driving the need for innovative technologies designed to help our customers better understand the molecular makeup of disease so they may more effectively treat cancer in the future,” said Joydeep Goswami, president of Clinical Next Generation Sequencing and Oncology for Thermo Fisher Scientific. “Thermo Fisher is committed to enabling breakthroughs in the laboratory through its broad spectrum of solutions for the development of future clinical applications.”

New Featured Products at AACR Include:

- [Ion Torrent™ OncoPrint™ Knowledgebase Reporter](#) via Thermo Fisher Connect, powered by Thermo Fisher Cloud, enables researchers to put sample-specific variants into context by linking them to labels, guidelines and global clinical trials. The tool also helps create a custom, lab-generated report in any of the 10 language templates built into the software. Updates to the data and improvements to enhance the user experience and reports are performed each quarter.
- The new Applied Biosystems™ TaqMan® Digital PCR Liquid Biopsy Assays are a set of 100+ wet-lab validated assays that complement the family of Thermo Fisher’s OncoPrint cfDNA panels. The new product is ideally suited for translational oncology researchers who are seeking a solution for a small numbers of targets or others seeking a next-generation sequencing confirmation solution at < 0.1 percent allele frequency.
- Developed for use in conjunction with the new Bluetooth-enabled Thermo Scientific E1-ClipTip electronic pipettes, the [Thermo Scientific My Pipette™ Creator](#) is the first cloud-based application designed to enable efficient, centralized programming of connected pipettes, as well as secure storage and sharing of protocols between pipettes and colleagues within the lab. Offering a library of pre-programmed protocols for the E1-ClipTip pipettes and Thermo Fisher Scientific reagent kits, the My Pipette Creator application allows users to save time, enhance consistency and minimize programming errors to help achieve reproducible, reliable and traceable results.
- Gibco™ Cancer Cell Culture Starter Kits provide researchers with a convenient package of reagents for the culture and transfection of cell types frequently used in cancer research. Based on data from hundreds of

cancer research publications, Cancer Cell Culture Starter Kits are currently available for breast, lung, prostate and liver cancer cells and contain the most commonly used reagents to help start cancer cell culture quickly and achieve successful transfection.

The OncoPrint™ Comprehensive Assay v3 expands the family of assays for cancer clinical research with updated content of 161 target genes, including hotspot SNVs and indels, CNVs and gene fusions variants that are optimized for Ion™ Chef and Ion S5™ workflow.

Scientific Posters

Thermo Fisher scientists will present nine posters on topics ranging from targeted NGS and digital PCR solutions to evaluate tumor microenvironments and verify liquid biopsy data, to new approaches for epigenetic reprogramming and genomics screening using CRISPR technology. Featured posters include:

Sunday, April 2, 2017

- TaqMan Liquid Biopsy Assays targeting the TERT promoter region. Section 31, poster board 8, abstract 746. Presented by Marion Laig, senior product manager, Genetic Analysis, Thermo Fisher Scientific from 1-5 p.m.
- Orthogonal validation of OncoPrint cfDNA panel data with digital PCR using TaqMan Liquid Biopsy Assays. Section 31, poster board 5, abstract 739. Presented by Vidya Venkatesh, senior product manager, Genetic Analysis, Thermo Fisher Scientific from 1-5 p.m.

Monday, April 3, 2017

- Sequencing the circulating and infiltrating T-cell repertoire on the Ion S5. Section 27, poster board 9, abstract 1631. Presented by Geoffrey Lowman, Ph.D., senior staff scientist, Clinical Sequencing and Oncology, Thermo Fisher Scientific from 8 a.m.-noon.
- Functional genomics screening using LentiArray™ CRISPR libraries and CellSensor™ assays. Section 35, poster board 8, abstract LB-116. Presented by Chetana Revankar, Ph.D., senior staff scientist, Cell Biology R&D, Thermo Fisher Scientific from 1-5 p.m.

Tuesday, April 4, 2017

- Defining the relevant genome in solid tumors. Section 23, poster board 7, abstract 3811. Presented by Habib Hamidi, Ph.D., senior staff scientist, Clinical Sequencing and Oncology R&D, Thermo Fisher Scientific from 8 a.m.-noon.
- Sequencing the human TCRβ repertoire on Ion S5. Section 23, poster board 3, abstract 3567. Presented by Denise Topacio-Hall, scientist III, Clinical Sequencing and Oncology R&D, Thermo Fisher Scientific from 8 a.m.-noon.

Wednesday, April 5, 2017

- A targeted NGS solution to evaluate gene expression signature of the tumor microenvironment from 40 NSCLC FFPE and matched fresh frozen samples. Section 15, poster board 20, abstract 5364. Presented by Yuan-Chieh Ku, Ph.D., scientist III, Clinical Sequencing and Oncology R&D, Thermo Fisher Scientific from 8 a.m.-noon.
- An NGS workflow to detect down to 0.1 percent allelic frequency in cfDNA for breast and colon cancers. Section 17, poster board 7, abstract 5396. Presented by Dalia Dhingra, Ph.D., staff scientist, Molecular Biology Clinical Sequencing and Oncology, Thermo Fisher Scientific from 8 a.m.-noon.

Thursday, April 6, 2017

- Measuring gene expression at the tumor microenvironment: A comparison between Counter PanCancer

Immune Profiling Panel and Oncomine Immune Response Research Assay. Section 15, poster board 19, abstract 5363. Presented by Fiona Hyland, director, R&D (Bioinformatics), Clinical Sequencing and Oncology, Thermo Fisher Scientific, from 8 a.m.-noon.

For more information on Thermo Fisher's activities at AACR 2017, please visit [here](#).

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of \$18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Contact:

Thermo Fisher Scientific
Mauricio Minotta, +1 760-929-2456
+1 760-805-5266 (mobile)
mauricio.minotta@thermofisher.com

<https://thermofisher.mediaroom.com/press-releases?item=122395>